As in previous brigatinib studies, the most common AEs in this J-ALTA cohort included elevated CPK, hypertension, elevated amylase, elevated lipase, hepatic enzyme abnormalities, and gastrointestinal AEs. Here, PIK3C2A is linked to Hypertension.